Why drug safety should not take a back seat to efficacy

PLoS Medicine

Volumn 8, Issue 9, 2011, Pages

[No Author Info available]

Author keywords

[No Author keywords available]

Indexed keywords

DICLOFENAC; NONSTEROID ANTIINFLAMMATORY AGENT; ROFECOXIB;

ADVERSE DRUG REACTION; ARTICLE; CARDIOVASCULAR RISK; CLINICAL STUDY; DEATH; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; DRUG SAFETY; DRUG SURVEILLANCE PROGRAM; HOSPITALIZATION; OBSERVATIONAL STUDY; PHARMACOEPIDEMIOLOGY; PRESCRIPTION; STANDARD;

EID: 80053339519     PISSN: 15491277     EISSN: 15491676     Source Type: Journal    
DOI: 10.1371/journal.pmed.1001097     Document Type: Article

References (9)

1. Pirmohamed M, James S, Meakin S, Green C, Scott AK, et al. (2004) Adverse drug reactions as cause of admission to hospital: Prospective analysis of 18,820 patients. BMJ 329: 15-19.
2. Strom B, (2004) Potential for conflict of interest in the evaluation of suspected adverse drug reactions. JAMA 292: 2643-2646.
3. Carpenter D, Zucker EJ, Avorn J, (2008) Drug-review deadlines and safety problems. N Engl J Med 358: 1354-1361.
4. Golder S, Loke YK, Bland M, (2011) Meta-analyses of adverse effects data derived from randomised controlled trials as compared to observational studies: Methodological overview. PLoS Med 8 (5): e1001026 doi:10.1371/journal.pmed.1001026.
5. McGettigan P, Henry D, (2011) Cardiovascular Risk with non-steroidal anti-inflammatory drugs: Systematic review of population-based controlled observational studies. PLoS Med 8 (9): e1001098 doi:10.1371/journal.pmed.1001098.
6. European Network of Centres for Pharmacoepidemiology and Pharmacovigilance. Home page. Available:http://www.encepp.eu/.
7. Schneeweiss S, Avorn J, (2011) Postmarketing studies of drug safety. BMJ 342: d342.
8. Laine C, Horton R, DeAngelis CD, Drazen JM, Frizelle FA, et al. (2007) Clinical trial registration - Looking back and moving ahead. N Engl J Med 356: 2734-2736.
9. CONSORT: Transparent Reporting of Trials. Home page. Available:http://www.consort-statement.org/.